Loss of Cdk5 activity in many cancers results in persistent overexpression of the interferon regulatory factors IRF2 and IRF2BP2, two PD-L1 transcriptional repressors that negatively regulate PD-L1 expression in tumor cells. Here, CDK5 is linked to cancer.